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In the past five years, it has been reported that certain 
dicarboxylic acids (C8 - C 1:J) and azelaic acid (C9) (AZA), 
in particular, have a rema rka ble effect in the manage-
m e nt of lentigo maligna, human malignant melanoma, 
and certain disorders of hyperpigmentation. Preclinical 
trials, therefore, were undertaken in order to evaluate 
the effectiveness of AZA as a depigmenting agent and as 
a chemotherapeutic agent. Twenty -seven uniformly 
black pigme nted gui nea pigs were given topical appli-
cations of various concentrations (3, 5, 10, 15, and 20%) 
of AZA preparations for 8 weeks, and their effects on 
the melanocy tes of epilated skin of the backs and the 
nonepilated ears of guinea pigs were compared to the 
effects of w e ll-known de pigme nting agents . Whereas 4 -
isopropylcatechol, monobenzy lethe r of h y droquinone, 
monoe th y lether of hydroquinone, h y droquinone, and 4 -
hydroxyanisole were found to be selectively cytotoxic to 
me lanocy tes in black-skinned guinea pigs, AZA has little 
or no visually recognizable effect on melanocytes in 
these animals. The therapeutic effect of local s.c . injec-
tions of various concentrations of AZA preparations on 
the development ofs.c. implanted B-16 melanoma tumor 
was evaluated in 96 C57BL/6J mice. In addition, 31 
BDF1 mice, implanted i.p. with B-16 m elanoma tumor, 
w ere used to assess the effect of 100-500 mg/kg concen -
t rations of AZA administered i.p. In both studies, AZA 
revealed no s ignificant tumoristatic or tumoricidal ef-
fect on t h e s ize, color, and g rowth of m e lanoma. The 
effect of AZA was also evaluated on S-91A (melanotic 
or pig me nted) and S-91B (amelanotic) human melanoma 
cells in culture. Low concentrations (lo-r. and 10-3 M) of 
AZA had no inhibitory effect on the growth of these 
cells. Only at higher concentrations (>10-3 M) was a 
cytotoxic e ffect o n ce ll viability observed. These obser-
vations indicate AZA is not se lectively cytotoxic to nor-
mal and proliferative melanocytes and has no apparent 
inhibitory e ffect on the formative process of melanin 
pig me ntation. 
In 1978, Nazza ro-Porro eta! proposed a specific, causative 
relationship between the fun ga l infection a nd hypop igmenta-
Manuscript received August 20, 1984; accepted for publication March 
22, 1985. 
This work was supported by a grant. from the Rev lon Resea rch 
Center, Inc., Edison, New .Jersey and by Grant No. 5-ROl-CA-05003-
25, awa rded by the National Cancer Institute, Department of Health , 
Educati on, and Welfare. 
Reprin t. requests to: Madhu A. Pathak, M.B. , M.S., Ph.D., Depart-
ment of Dermatology, Massachusetts Genera l Hospi tal, Boston, Mas-
sachusetls 0:2 J 14. 
Ahbreviat ions: 
AZA: azelaic acid (nonanedoic acid) 
dopa: :1 ,4-dihydroxyphenylalan ine 
HQ: hydroquinone 
4 -I PC: 4-isopropylcatechol 
4-0 HA: 4-hydroxyanisole 
MBEHQ: monobenzylether of hyd roquinone 
MEEHQ: monoet hylether of hyclroquinone 
t ion in tinea (pityriasis) ve rs icolor. They reported certain eli-
carboxylic acids (C8-C 1 :~) and AZA (a C9 dica rboxylic acid), in 
particular, are competitive inhibitors of tryosinase in vit ro [1 ,2] 
and exhibit pronounced benefic ial effects in vivo on the treat-
ment of hyperpigmentary di sorders such as chloasma (me-
las ma), tox ic melanoderma, and poikiloderma of Civatte [3]. 
They also observed aze laic ac id (AZA) caused damage to normal 
melanocytes [2,3]. In studies on mice wit h t ransp lanted Hard-
ing-Passey melanoma, they further reported t he i.p., s.c., and 
oral administrat ion of C9 , C12 , and C 14 di carboxylic acids sig-
nificantly retarded the tumor growth and prolonged the survival 
t ime of t umor-bearing mice [2,3]. Histologic and electron mi-
croscopic examination revea led lipid dege neration of malignant 
melanocytes and diminished metabolic act ivity as exp ressed by 
poorly deve loped Golgi apparatus, a reduced number of hypo-
pigmented melanosomes, and associated membrane changes. 
Furthermore, they reported a striking therapeutic effect in 
lentigo maligna with clinica l a nd histologic reso lution of le-
sions, when a topical prepa ration conta ining 15% or 20% AZA 
was applied to t he lesions; a progress ive disappearance of 
abnormal melanocytes at t he basal and suprabasal layers was 
reco rded, a nd t he abnorma l melanocytes were observed to be 
replaced by "normal mela nocytes" [2,4,5]. In addit ion, clinical 
regression in human maligna nt melanoma was also seen when 
AZA was applied topically and given orally. Twenty-three pa-
tients with clinically diagnosed maligna nt melanoma were 
t reated with topical cream (20%) and oral (10- 15 g da ily) AZA 
for 1- 12 weeks. Clinica l improvements were observed in all 
patients. AZA a rrested growth and caused flattening and regres-
sion of t he size a nd t he adva ncing edges of t he tumor [6]. 
Recently , Pehamberger et a! a lso reported AZA signiticant ly 
reduced the proliferation of two melanoma ce ll Jines (CRL 
1424-human and CCL 53 .1 -mouse) but had no adverse effects 
on ce ll viability [7]. The review by Breathnach eta! [3] provides 
additional pert inent references to t he various propert ies of 
AZA. 
222 
In vitro and in vivo studies were, therefore, carried out to 
evaluate t hese apparent se lective cytotoxic and depigment ing 
properties of AZA and its potent ial value as a chemotherapeutic 
age nt . In blac k pigmented gu inea pigs, t he dep igmenting effects 
of various concentrations of AZA preparations were compared 
with t he effects of t he known depigmenting agents: 4-isopro-
pylcatechol (4-IPC), hydroquinone (HQ), 4-hydroxyanisole (4-
0HA), monobenzylether of hydroquinone (MBEHQ) , a nd 
monoethylether of hydroquinone (MEEHQ) . The effect of AZA 
as a chemotherapeutic age nt was evaluated in mice bearing 
subcutaneous B-16 melanoma tumors as well as in mice bearing 
i.p . impla nted B-16 mela noma tumors. The in vitro effect of 
AZA on the growth and survival of S-91A (melanotic) a nd S-
91B (amelanotic) melanoma cells was also evaluated . 
MATERIALS AND METHODS 
Cuta neous Depigmentation. with AZA and Other l<n.own. Depigmenting 
Agents 
Twenty-seven uniformly pigmented blac k-skinned adult (600 ± 100 
g) gu inea pigs (Eim hill Breeding Laboratories, Chelmsford , Massachu -
setts) were used to evaluate the effectiveness of AZA as a depigmenting 
agent. Reagent grade AZA was purchased from the Eastman Kodak 
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Compa ny, Rocheste r, New York . Prepa rations of crea ms contai nin g 3, 
5 10 15 a nd 20% AZA we re applied to the wax-ep ilated skin of the b~ck~ a nd t he nonepilated skin of the ea rs of gu inea pigs once daily for 
a pe riod up to 8 weeks. The 3, .5, I 0, and 20% AZA creams were made 
in a n ac id ma ntle crea m base, at pH 5.8- 6.0, con ta ining glyce ro l 
monostearate a nd aluminum acetate 18%, spe rmaceti 4%, sulfonated 
caste r o il 4%, acety lated la nolin (rnodulen) 7%, emulsifier and stabi -
lize r , isopropyl pa lmi tate (deity! ex tra ) :3 %, glyce rol 3%, lactic ac id 
0.25 % , H 20 60%, and prese rvatives (a nt iox ida nts) 0. 15%. The 3, 5, 10, 
and 20% AZA crea ms in ac id mantl e base were <l pplied da ily (6 clays/ 
week) for 6 weeks (4.5 days) to 20 a nima ls divided into 4 groups. The 
15% AZA cream was made in t he following base: amerchol 4.3%, olive 
o il 2.9%; glyce ryl monostearate 5.0%, cety l alcohol 2.4 %, stearic ac id 
2.4 % , t ri ethanolamine 0.9 %, propylene glyco l 2.1 %, and distilled wate r 
65 % . A group of 8 a nimals received 15% AZA c ream for 8 weeks. In 
add ition, 2 gu inea pigs received topica l application of a 15% solu tion 
of AZA in 95 % ethanol to asce rta in t he contact irritat ioP effect of t his 
deca rboxylic acid . Eac h ~inea pig had a t leas t a 56 cm2 a rea for product 
app lication. Four microli te rs of AZA prepa ration were applied to each 
cm2 a r ea of t he test site . The depigment in g ac tivi ty of top ica l AZA was 
comp a red to t he known depigment ing agents: 3% 4- !PC, 3% 4-0 HA , 
3% MBEHQ, 3% MEEHQ, a nd 3% HQ. These chemica ls were pur-
chased eithe r from S igma Chemical Co ., St. Louis, Missouri , or from 
Aldric h Chemica l Co. Mi lwaukee, Wisco ns in . The chemica ls were 
app li e d to the epilated backs of pigmented gu inea pigs in a crea m form 
us in g t he same vehicle (ac id ma ntle base) as described above. Co ntro ls 
to compa re t he morphologic alterations or mela nocytes included epi -
lated, unt reated skin a nd vehicle- treated sk in (c ream base). 
Cutaneous depigmentation is max imal by the end of 6 weeks. The 
degree of cutaneous depigme ntation was , t he refo re, evaluated weekly 
for up to 8 weeks according to t he foll owing crite ria: 0 = non e; ± = 
uncertain; + = speckles of depigmentation, weak reaction; ++ = mild 
depigmentat ion with some foci of no rma l skin colo r; +++= moderately 
st ro n g depigmentation with unifo rm loss o f ski n color: ++++ = white 
s k in ex hibi t ing tota l (strong) depigmenta tion with a lmost a total loss 
o f dopa-pos itive melanocytes. Unless othe rwise indicated , t he te rm 
con t rol refers to biopsy sites obta ined from t he ep ilated s kin t reated 
with e it her of the 2 bases used for preparing depigment ing creams. T he 
cream bases devoid of depigment.ing chemica ls (e.g. , AZA, 4 .. fP C, 4-
0HA, etc.) were applied da ily, 6 days per week for a pe riod of 8 weeks. 
Control b iopsies we re obtained at various t ime inte rva ls on t hose days 
whe n AZA-treated biops ies were needed for eva luating the morphologic 
and numerical a lte rations in melanocytes. Thiersch biopsies, approx i-
mately 1 cm2 from the product-trea ted tes t s ites and the co ntrol s ites , 
were obta ined a t 2-week interva ls up to 6 weeks and processed fo r 
me la n ocyte counts as described by Szabo [8 ] and Bleehan et al [9]. The 
biopsies were assessed fo r: (1) routine his to logy (hematoxylin -eosin 
s tai ning), (2) histoc hemist ry us ing 3,4-d ihydroxyphenyla lanine (dopa) 
incubation to dete rmine t he numerica l count of melanocytes and evi-
dence of a lte ra tions in the morpholo:,>y of rne la nocytes, a nd (3) ultra -
structural studies. E lect ron microscopic studies were ca rried out ac-
cording to the method outlined h.v .Jimbow et a l/1 0 ]. 
Che motherapy of B- 16 Mouse Melanoma 
The effect of va rious concentrations of AZA on the surviva l of B-16 
melanoma-bea ring mice was eva luated us ing adult male {22- 25 g) BDF, 
mice (J ackson Laborato ries, Ba r Ha rbor, Ma ine) . T he protocol es ta b-
lished by the U.S. National Cance r Insti tute, Bethesda, Maryla nd, for 
the testing of chemical agents aga inst animal tumors was foll owed 
[11,12 ]. Because of t he limi ta tions imposed by the ava ilabil ity of pure 
AZA and the required number of a nimals, t he effect of AZA on the 
growth of B- 16 melanoma tum or cell was examined in 2 phases a nd 
over a period of 9 mont hs. In the first phase, mice of Group 1 received 
mode rate ly high conce nt ra tions of butTered AZA (200- 400 mg/kg) at 
pH 7.4. In the second phase, mice of G roup 2 received low concen t ra-
t ions of buffered AZA (100 mg/kg a t pH 7.4 ), and mice of G roup 3 
received buffe red AZA a t high co nce nt ration (500 mg/kg at pH 3.2) 
and low co ncentrat ions o f AZA ( 100 mg/ kg, pH 3.4). The BDF, mice 
received 0.5 ml i.p. injec ti ons of B-16 melanoma-cell homogenate (1.0 
g tumor and 10 ml cold balanced sa lt solution) a nd then da ily injections 
o f 100, 200, 400, a nd 500 mg/kg AZA solutions. As a control, one group 
rece ived 0.5 ml t umor injection followed by injec tions of sa line solut ions 
w ith no AZA , and one group received no tumor and just 400 mg/ kg of 
AZA solution. The AZA solutions of 200 and 400 mg/ kg were neut ra l-
ized by NaO H to pH 7.4 resulting in the administ ration of 97 mg/ kg 
of sodium for eve ry 400 mg/kg of AZA. Non-neutra li zed solutions of 
AZA at 100 and !100 mg/kg were a lso evaluated with appropria te 
controls. The AZA so lutions were adminis te red s tarti ng l day a fte r the 
impla nta tion oft he t umor and dai l ~' injec t ions were ca rried out fort he 
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length of the surviva l of t he mice. The weight o f eac h mouse was taken 
every fifth day and postmortem examinations (necropsy) were per-
formed afte r t he death of each animal. The median surviva l t imes for 
each group were calculated. 
The effect of va rious co ncen t rations a nd the va ry ing pH of AZA 
solu t ions on the growth of developing tumor was a lso evaluated in adul t 
male (22- 25 g) C57BL/6J mice (Jackson Laboratories) . The freshly 
obtained tumor fragments from mice bea ring B- 16 melanoma were 
carefully diced in sa line solut ion and fragments conta ining approx i-
mate ly 1 x 106 cells were injected s.c. wi th t he a id of a trocha r into t he 
right inguina l a rea. Da ily, local a nd s.c. injections of buffe red (pH 5.6-
5.2) a nd unbuffered (pH 3.2-4.0) AZA solutions at 50, 100, 200, 300, 
and 400 mg/ kg were administered starting the day afte r implantation 
of t he tumor. T he unbuffered solutions were made using Krebs-Ringer 
solu t ion. The weight of t he mice was taken weekly, a nd the t umor 
weight was calculated from measurement of t he s ize of the tumor using 
a Vernier caliper and a cent imete r scale (11]. 
Chemotherapy of S-9/A and S-9 1 B Melanoma Cell Lines In Vitro 
The origin and maintena nce of t he melanoma cell lines used in t his 
study have bee n desc ribed previously [1 3,14]. The S-91A and S-9 18 
cell lines represent p igmented (melanot ic) and nonpigmented (amela-
notic) huma n melanoma cell lines. Both cell lines have been mainta ined 
in McCoy's 5A medium supplemented with 10% feta l ca lf serum , 100 
11 g streptomycin/ ml , and 100 U of penicillin / ml in an atmosphere of 
5% C02 humidi fi ed air at 37"C. Approximate ly l X 105 ce lls/well / ml of 
media for S-91 B were plated in Linbro mult iwell t issue culture t rays 
and incubated at 37"C for 24 h. When t he ce lls were in t he log phase 
of growth , t he old medium was aspirated gently and was replaced with 
l ml of new growt h medium containing eit her of t he 4 drugs (4-0H A, 
4- IPC, HQ, AZA) a t concent ra tions ra nging from 10-5 to 10-2 M . The 
solubil ity of AZA at room temperature is app rox imate ly 2.5 g/ liter; 
t herefore, AZA could be eas ily solubili zed in t he medium at 10- 5 to 10-2 
M range. The ce lls conta ining the depigmenti ng agents at t hese va rying 
concent rat ions were incubated at 48 h at 37"C. Subsequently, the cells 
were ha rvested and counted in a Coulte r counte r. The cell morphology 
was observed during a nd on d iffe rent days of incubation . For routine 
purposes, t he v iab ili ty of cells t reated wit h different depigmenting 
chemica ls was assessed us ing the commonly used t rypan blue dye 
exclus ion technique /1 5 ], a nd a visua l count of unsta ined "live'' ce lls 
based on t he assumpt ion t he viable cells wi ll exclude t ryp a n blue and 
the nonviab le ce lls will absorb the dye. Studies on the inhibition of the 
growth at different concent rations were car ried out in t riplicate, and 
the resul ts are expressed as t he percentage of inhibi tion of growth as 
compared to t he co ntrol. 
RESULTS 
Effect of AZA on Normal M elan.ocytes (Cutaneous 
Dep£gmentat£on) 
The effect of va rious concent rations of AZA on cutaneous 
depigmentation in comparison with the other known depig-
menting agents is shown in Table I. T he wax-epilated skin of 
the backs and t he nonepilated skin of the ears of guinea pigs 
during the 8 weeks of treatment showed an uncertain (slight) 
TABLE l. Comparison of the effects of topical AZA and known 
depigmenting agents on cutaneous depigmen tation in guinea pigs 
No. of Skin depigmentation at week 
AZA cone guinea 
pigs 2 3 5 6 
3% 4 0 ± ± ± + + 
5% 2 0 ± ± ± ± + 
10% 7 0 0 0 ± + + 
15% 8 0 0 0 0 0 0 
20% G 0 ± + + + + 
Skin depigmentation at week 
Other agents 
2 3 5 
3% HQ" 0 ± + + ++ 
3% 4- IPC" ± + ++ +++ ++++ 
3% 4- Hydroxya nisole" ± + ++ +++ +++ 
3% MBEHQ" ± + ++ ++ +++ 
3% MEEHQ" 0 ± ++ ++ +++ 
Depigment ation: 0 = Absent , ± = uncert a in , + = weak, ++ 
moderate, +++ = strong, ++++ = tota l. See a lso Materials and 
Methods . 
"Each of these chemicals has bee n tested on a t least 10 anima ls . 
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degree of depigmentation (0 to +) in comparison with the 
kn own depigmenting age nts such as 3% 4- IPC, 3% 4-HQ, 3% 
4 OHA, 3% MBEHQ, and 3% MEEHQ, which showed signifi -
cant dep igmentation (up to +4) . Top ically app lied, AZA at 3, 
5, 10, 15, and 20% concent rations produced no recognizable 
cutaneous effects in t he first week of t reatment. By t he end of 
t he second and t hird week, most of t he t reated a nimals exhib-
ited a moderate degree of irritat ion and desquamat ion. H igher 
concentrations of AZA (l0- 20 % ) caused an eczematous oozing 
reaction and was more irri ta nt t han t he formula t ion contai ning 
a low concentrat ion of AZA. By t he end of t he t hird and fourth 
weeks, t here was no ev idence of cutaneous depi gmentation. T he 
sk in of severa l animals rece iving 10, 15, a nd 20% AZA ex hibited 
ev idence of posti nll ammatory hype rpi gmentation. Contrary to 
t his, t he skin of an ima ls t reated with 4- IPC 3%, 4-hydroxyani-
so le 3%, MBEHQ 3%, and MEEHQ 3% exhibi ted a strong 
degree of dep igmentation (Table I) ; t he treated sk in s ites ap-
peared almost wh ite a nd amela notic. By t he end of t he fift h 
and sixth weeks, a few newly growing hair shafts distributed 
randomly at the AZA-treated s ites appeared white, indicating 
li t tle or no effect of AZA on t he proliferative mela nocytes of 
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the ha ir bulbs . Contrary to t his, sk in s ites t reated wit h 4-IPC, 
MBEHQ, 4-0HA, and MEEHQ revealed a s ignifica nt ly higher 
frequency of leukotrichia. The control skin sites t reated for a 
period of 8 weeks wit h two different vehicl es revealed no 
irritation reaction; a mild desquamation resulting from the 
trauma of ep ilation could be seen in several s ites. Microscopic 
examination of several control skin biopsies obta ined from sites 
treated with 2 vehicles revealed normal-appearing skin very 
similar to the epila ted but nont reated skin, suggesting t hese 2 
vehicles were nonirritant. The incubation of biopsies in the 
buffered dopa solut ion at various t ime in te rvals up to 6 weeks 
revealed no s ignificant numerical cha nges in t he number of 
melanocytes in t he AZA-treated skin s ites (Table II) , whereas 
skin sites treated with 4- IPC, 4-0HA, MBEHQ, and MEEHQ 
revealed a total loss of functional melanocytes (Fig 1). The 
morphology of control skin melanocytes and melanocytes after 
treatment with 10 a nd 20% AZA is shown in Fig 1A, 1B, and 
1C, respectively. The cell s appear active a nd dendri t ic, and 
there is no evidence of the loss of tyrosi nase activity as revealed 
by examinatio n of dopa -incubated biopsies. Examination of the 
dopa-incubated biopsies by light microscopy revealed no mor-
TABLE II. Dopa-po:;itiue melanocyte count/mm 2 in guinea-pigs treated topically with 15% AZA cream 
Initial 2 Weeks 4 Weeks 6 Weeks 
Guinea pi~: // 
Control/treated Control/treated Control/treated Control/ treated 
----
1 515 483 483 489 467 492 480 470 
2 492 499 499 486 499 473 505 467 
3 464 476 396 460 484 426 416 467 
4 486 473 662 53 1 461 424 464 476 
5 424 424 320 378 419 499 460 486 
6 426 416 348 540 455 483 489 486 
7 419 348 419 403 486 486 492 480 
8 502 486 380 374 492 456 470 486 
Average± SD 466 ± 39 451 ±51 439 ± 83 458 ± 66 470 ± 26 468 ± 29 473 ± 28 477 ± 8 
FI G 1. These figu res illustrate t he in vivo effec ts of AZA, 4- lPC, MBEHQ, and MMEHQ on guinea-pig melanocytes. A = Contro l, epilated 
back skin t rea ted with vehicle a lone; B = 10% AZA ; C = 20% AZA; D = 3% 4- !PC; E = 5 % MBEHQ; and F = 1% MMEHQ (X 550). Pigmented 
guinea pigs we re treated da ily, 5 t imes per week , for 8 weeks. Normal-appearing, dopa-positive dendritic melanocytes can be seen in A-C. In D-
F, progress ive loss of melanocytes is see n. A few dopa-pos itive mela nocytes appear hypertropic in D and E at 5 and 6 weeks of t reatment. 
Eventually by 6- 8 weeks, melanocytes degenerate as shown in F. 
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pho lo gic changes in melanocytes t reated wit h AZA, whereas 
mela n ocytes treated wi t h t he kn own depigmenting agents 4-
IPC, 4-0HA, MBEHQ, a nd MEEHQ revealed significant de-
generative changes wit h t he loss of dendri tes and perikaryon. 
The ultrastructural obse rvations of AZA-treated skin sites (10 
a nd 15% prepa rations) showed no selective changes in t he 
morphology of t he melanocytes. The melanized mela nosomes 
appeared norma l, a nd t he other components of melanocytes, 
such as mitochondria, smooth and rough endoplasmic reticu-
lu m , and Golgi apparatus, appeared normal. We found no 
evide n ce of abnorma l vacuoli zation or accumulation of lipid 
droplets as reported by Breathnach et al [16,17] . No myelin-
like b odies, which a re ofte n seen in degenerating melanocytes 
[10], were observed; however, in many melanocytes, t he mito-
ch o ndria appeared enlarged in size. H ematoxylin and eosin-
stain ed t issue sections of AZA- treated biopsy specimens re-
vealed a mild hyperplasia of the epidermis. The pigmented cells 
appeared normal, or in many instances proliferative. The pig-
men t incontinence in t he dermis was not seen. The influx of 
infla mmatory cells was minimal at low concentrations. At high 
con cent rations of AZA , a mild infla mmation cha racterized by 
migr ation of lymphocytes and polymorphonucleocytes was ob-
serve d. 
Effect of AZA on the Growth of B-1 6 Melanoma Tumor 
The effect of various concent ra tions of AZA on t he median 
surv ival t ime of mice bea rin g B-16 mela noma tumor i.p. a nd 
o n t h e development of s.c . grown tumor is shown in T ables III 
and IV. AZA showed no benefi cial or t herapeut ic effect on t he 
media n surviva l t ime of mice bea ring int raperi to nea l t umor 
(Table III) . Eve n t hough statistically not s ignificant, tumor-
bearing cont rol mice rece iving no AZA survived longer than 
m ice being t reated wit h AZA. Mice of Group 1 receiving mod-
e rate ly high concent rations of buffered AZA (200-400 mg/kg) 
at pH 7.4 survived as long as t he tumor-bearing cont rol a nimals 
receiving saline injections wi thout AZA. Mice of Group 2, 
rece iving low concentrations of buffered AZA ( 100 mg/kg) also 
sh ow ed negligible differences on t he medium survival t ime. 
T h e r e was no evidence of a statistica lly significant association 
of s urvival days between t he cont rol group a nd t he AZA- t reated 
group (n = 10, p > 0.05). On t he other ha nd, mice of Group 3 
rece iving unbu ffered AZA at 100 and 500 mg/kg concent ration 
d id not survive long. B-16 melanoma t umor-bearin g cont rol 
m ice usua lly survived 18- 21 days. The unbuffered AZA caused 
irri tation, ulce ration, and nec ros is at t he site of injection , a nd 
m ice died ea rly because of appa rent tox ic pH effect of AZA. 
Postmorte m examination of t he mice revea led in all cases 
exten sive tumor growt h in the abdominal cavity with invasion 
into the thorac ic area . In addi t ion , t here was no vis ible cha nge 
in t h e color of the tumor. 
The effect of AZA on t he development of s.c . grown tumor 
was minimal (Table IV) . The buffered so lu t ions of AZA showed 
no t umoristatic or tumori cidal effects. Although the mean 
we ig ht and size of B-1 6 mela noma tumors in mice of Group 2 
(100 mg/kg AZA at pH 3.3) and Group 3 (200 a nd 300 mg/kg 
AZA at pH 3.5) showed a n appa rent dimuni t ion in s ize sug-
gesting AZA was tumori static, one should be caut ious in inter-
p re ting such data . The unbuffered so lutions appea red to be 
irr itant as evidenced by t he pronounced gnawing at s ites adja-
cen t to t he tumor. This effect resul ted in t he loss of tumor 
mass by t he t hird a nd fourt h weeks in approximately 50% of 
t he mice. When t he average we ights of t he s.c. developing 
tum or in mice treated wi t h local applications of AZA were 
compared, it was clear AZA did not inhibit the growth of t he 
tu m or. There was a 10- to 15- fold increase in t he tumor volume 
between t he first and t hird weeks. The majori ty of the a nimals 
began dy ing a fter 3 weeks of injections, a nd t hose t hat survived 
con t inued to show an increase in tumor mass with no evidence 
of t umor regress ion. The low average weight often resul ted 
from t he mice hav ing destroyed t heir tumors, thus lowering all 
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TABLE III . Median survival Lime of BDF, mice bearing B-16 
melanoma tumor intraperdoneally treated with various concentrations 
of AZA 
No. Percent of 
Tumor AZA of mice Median survival {mg/kg) 
mice growing time in days tumor 
Group 1 a 
No tumor 400 8 0 180.0 
+ 0 8 100 21.0 
+ 400 8 100 20.0 
+ 200 7 100 19.0 
Group 2a 
+ 0 10 100 18.0 
+ 100 10 100 16.5 
Group 3b 
+ 0 10 100 27 .0 
+ 0 10 100 26.5 
+ 100 10 100 4.0 
+ 500 10 100 2.0 
+Tumor bea ring. 
"Buffered AZA injected i.p. daily; pH 7.4. 
b Unbu ffe red AZA injected i.p. daily; pH 3.4 . 
TABLE IV. Mean tumor weight and size of developing subcutaneous 
B- 16 melanoma tumor in C57BL/6J mice receiving subcutaneous 
injections of AZA 
Mean tumor weight. and 
AZA dose pH No. of mice size at 22 days {mg/k g) at 22 days Weight {mg) Size {mm 2 ) 
Group 1 
Control 0 7.4 7/8 2849 ± 1209 343 ± 105 
AZA 50 6.6 7/8 4301 ± 2004 451 ± 140 
AZA 100 6.6 6/8 4391 ± 2385 455 ± 167 
AZA 200 5.7 7/8 5706 ± 1752 565 ± 107 
Group 2 
Control 0 7.0 8/8 1965 ± 965 268 ± 109 
AZA 50 3.4 7/8 3877 ± 2160 440 ± 140 
AZA 100 7.4 7/8 2776 ± 776 326 ± 62 
AZA 100 3.3 4/8" 790 ± 550 130 ± 133 
Group 3 
Control 0 7.4 7/8 2859 ± 1559 337 ± 132 
AZA 200 3.5 5/8" 456 ± 815 88 ± 113 
AZA 300 3.6 6/8a 1490 ± 1281 213 ± 133 
AZA 400 3.4 5/8a 0 0 
AZA 500 3.2 0/8" 0 0 
a Many mice chewed their skin at the injection sites result ing 111 
gnawing-out of the tumors and over 50% died within 22 days. 
averages. Ulcers were evident at t he unbuffered AZA injection 
sites even in non-tumor-bearing mice. 
The Effect of AZA on S-91A and S -91B Cell L ines 
The effect of various concentrations of AZA on t he growth 
of S-91A and S-91B melanoma cell lines is shown in Table V 
and its effect in comparison wit h various concent rations of 4~ 
OHA, 4- IPC, and HQ is shown in Fig 2. At low concent rations, 
10- 5 to 10-" M, AZA was not cytotox ic. At t hese concent rations, 
t he cells were found to remain attached wi t h a tendency to 
round . The cells that were attached appeared normal as evi-
denced by the t rypan blue dye exclusion technique. As t he 
concen t ration of t he drug was increased (1 0-2 M) t he cells 
tended to round, swell , and lose t heir morphology. T he cells, 
soon after contact wit h 10- 2 M AZA, became t rypan blue posi-
t ive. The cytotoxic effects of AZA (10- 2 M) was similar on 
pigmen ted and nonpigmented cells. Cont rary to t his, 4-0HA, 
4-IPC, and HQ were cytotox ic at much lower concent rations 
(10- 5 to 10- 4 M), a nd most of t he cells seemed to degenerate 
wi t h cytotoxicity increased against t he pigmented cells . On a 
molar basis, 4-0HA a nd 4- IPC were more inhibitory to t he 
growt h of melanocytes than was AZA. 
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DISCUSSION 
T he ini t ia l obse rvations by Nazza ro-Porro et a! on AZA 
prov ided an in te resting exp lanation of t he hypopigmentation 
so com monly seen in patients wi t h t inea versicolor [1 ,3 ]. Their 
in vit ro experi ments revealed a causative relat ionship between 
t he infecting fun gus a nd its metabolic act ivity ge nerating CR-
C1:3 d icarboxy lic acids t hrough t he enzymatic ox idation of fatty 
ac ids [1,2]. T heir subsequent studies with laboratory anima ls 
wit h t ranspla nta ble Harding-Passey melanoma revea led t hat 
da ily i.p. or S .C. injections or oral administrat ion of c,l- C\2 
dica rboxyli c ac ids remarkably delayed t he tumor growth and 
prolonged t he su rv ival t imes of tu mor-bea rin g mice [2,3]. These 
investigato rs furt her showed t hat patients wi t h lent igo maligna, 
when t reated wi t h AZA, responded wit h progress ive reduction 
in t he nu mber of mela nocytes and re markable clinical improve-
ment wit h return to norma l clinical as well as histologic ap-
pea rance of t he skin [2,4,5]. Furt her cl inical t ri als wi t h AZA 
revea led t hi s d ica rboxy lic ac id exhi bited a t herapeut ic effect on 
lent igo ma ligna as well as a profound effect on patients wit h 
invasive mela noma [3,6]. The clinica l a nd histopathologic ob-
se rvations on lent igo maligna t reated wit h 20% topical AZA 
have -been recently supported by Leibl eta! [18]. Throughout 
t heir studies in hu mans and in laborato ry a ni mals, t hese inves-
t igators have reported negligible effects [2,3,14] on normal cells, 
and, in ge neral, have supported t he view t hat AZA has no 
appa rent side effects nor is it selective ly cytotox ic to normal 
melanocytes [2- 4,6,19]. T hey believe t hat AZA acts specifically 
against hype ractive a nd ab normal mela nocytes wit h li ttle or no 
effect on t he majo ri ty of normal melanocytes. In addit ion , t hey 
have not foun d an LDoo va lue in mice us ing doses up to 1000 
mg/kg [19]. 
TA BLE V. Effect of AZA on S-9 /A and S -9 / B melanoma eel/,, in. 
cultu re 
Mea n no. of me lanocyteso 
Treatme nt T ime S-9 lA Pe rcent 
pigmented co nt rol 
None (con i rol) Day zero 0.73 X 105 
No ne (control) 48 h 2 .. X 10'' 100 
Jo-• M AZA 48 h 2.5 X 105 111 
10-:• M AZA 48 h 2.1 X 105 83 
10- 2 M AZA 48 h 0.66 X 105 28 
S-91B Percent 
No npign·w nt ed control 
None (control) Day zero 0.46 X 105 
None (control) 48 h 3.5 X JO" 100 
10-·• M AZA 48 h 3.4 X 105 96 
JO-" M AZA 48 h 3.0 X 10'' 84 
10- 2 M AZA 48 h 0.89 X 105 14 
--- ----
"Each concentration effect was evaluated in trip licate. 
80 
'"' 60 ~ 
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While we have not t ried to reproduce t he interesting findi ngs 
of t hese investigators, we have attempted to evaluate t he cyto-
tox ic and tumoricidal effect of AZA on normal as well as 
malignant melanocytes. We have found no ev idence AZA func-
tions as a cytotoxic or as a tumoricidal agent in concentrations 
up to 10-3 M . 
Wi t h several derivatives of H Q (e.g., H Q, MBEHQ, and 
MEEHQ), several catechol derivatives (e .g., 4-IPC, 4-hydroxy 
butyl catechol) , and several thiol compounds (e.g., mercapto-
ethanolamine) we have found invariably t hat a cytotoxic agent 
to normal melanocytes causes cuta neous depigmentation both 
in animal and huma n skin [9,20,21] . T hese agents are not only 
cytotox ic to normal, nonproliferative melanocytes, but they 
equally affect proliferative, hypertrophic, and nonmalignant 
melanocytes. By visual observations, histochemical staining of 
dopa-posit ive melanocytes, and electron-microscopic ul t ra-
structural studi es, we have found no ev idence t hat AZA in the 
10- 6 to 10- 3 M concent ration ra nge is selectively cytotoxic to 
normal or abnormal melanocytes and affects melanocyte mor-
phology and its function (formation, melanization , and t ransfer 
of melanosomes). Histochemical studies show both normal and 
malignant melanocytes are not affected a t physiologic concen-
trations ranging from 10-" to 10-a M of AZA. The perikaryon 
and t he dendri t ic processes appeared to be normal. In many 
biopsy specimens, t he AZA-treated cell s appeared to be proli f-
erative, more dendri t ic, and had enlarged perikaryon. The 
ul t rastructural studies showed normal-appearing melanosomes, 
enlarged but intact mitoc hondria, li ttle or no accumulation of 
lipid droplets, and no cha nges in the Go lgi apparatus or the 
rough a nd smooth endoplasmic reticulum. The data shown in 
Tables I and II indicate t hat AZA in va rious concentrations 
ranging from 3-20% had no detectable effect on t he fun ctional 
activi ty of normal pigment -producing cell s. It should be realized 
t hat in epilated skin, t he melanocytes were p roliferative and 
hypert rophic, and while ot her depigment ing agents shown in 
T able I selectively affected mela nocytes, AZA failed to inhibit 
or a lte r t he functional state of t hese active melanocytes. From 
previous experience wit h other cutaneous depigment ing and 
melanoma chemotherapeut ic agents, we have not encountered 
an agent t hat selectively affects malignant melanocytes but 
spares the normal melanocytes. On the cont rary, phenols, cat-
echols, and t hiol compounds not only can selectively destroy 
normal pigment -producing cells, but will a lso exhibi t cytotoxic 
effects on malignant melanocytes (unpublished obse rvations). 
In studying t he effects of AZA on 2 melanoma cell lines (CRL 
1424-huma n and CCL 53. 1-mouse), the Viennese coinvestiga-
to rs Leibl et a! [18] and Pehamberger et a! [7] have recent ly 
obse rved AZA at 1- 4 X 10- 2 M concent ration to reduce t he 
proli fe ration of CRL and CCL melanoma cells but to produce 
no adve rse effects on cell viabili ty. They believed AZA reduces 
proliferatio n of melanoma cells due to a n inhibit ion of DNA 
synthesis. In terestingly, our la boratory studies in progress also 
FI G 2. This graph illustrates the ef-
fect, as a percentage of the control, of 
AZA, 4- !PC, HQ, and 4-0H A on the 
growth of S-9 1A and S-91B cell lines at 
48 h after exposure to various concentra-
tions of the depigmenting agents. On the 
left side are data pertaining to S-91A 
pigmented cell line, and on the right side 
are the data pertaining to S-9lB nonpig-
mented cell line. 
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indicate that exposu re of S-91A pigmented and S-918 nonpig-
mented mela noma cell s to 1 X 1o-·• to 1 X 10- " M concentrations 
of 4-0HA or 4- IPC resul ted in a significan t dec rease in DNA 
synthesis as ev idenced by t he inhibi t ion of ["H]thymidine in -
corporation. There was, however , no decrease in the de novo 
synthesis of total ce ll protein o r RNA, suggesting t hat 4-0HA 
o r 4- I PC, t he 2 poten t depigmenting agen ts, a lso affect the 
prolife ration of melanocytes in a ma nner similar to AZA as 
repo r ted by these Vi ennese investigators [7,18 ]. 
Tumor-bearing anima ls with i.p. o r s.c. transplantations of 
B-16 melanoma revea led no obv ious inhibi t ion of t umor growth 
when t reated with AZA. The dete rmination of tumor weight 
and size in s.c. tumor-bearing mice (T able IV) revealed no 
con sistent tumor inhibition. When AZA was administe red in a 
n e utralized pH range, it had no tumoricida l effect. There was, 
however, some ev idence of inhibi t ion when mice bea ring s.c . B -
16 melanoma tumor received nonbuffered (pH 3.2- 3.6) solu -
t io n s of AZA. These injections appeared to cause localized 
irritant reactions, many progress ing to ulceration. This resul ted 
in t h e pa rt ia l destruction of most tumor sites . The decrease in 
t h e ave rage tumor we ight and size, noted with unbuffered AZA 
in Table IV , could be att ributed to this mec ha nical removaL 
azzaro-Porro eta! have reported t heir results us ing AZA as a 
disodium salt or as a dimethyl ester [2]. We have applied AZA 
top ically and injected AZA both as t he disodium salt as well as 
the non buffered acid in varying co ncent rations and found nei-
t her to be inh ibitory to tumor growth up to the 10- " M conce n-
t ration ra nge. Unbuffered AZA preparations, when applied 
wpically or injected in traderm ally, were hi gh ly irritant and 
cau sed desquamat ion , postinll ammatory hype rpigmentation in 
gu inea pigs, and ulce ration in mice (Table II ). 
Our data on t he cytotox ic effects of AZA on t he S-91A 
(melanotic) and S-918 (a mela notic) me lano ma cell lines (Table 
V) fa iled to indicate any selective inhibitory effect of AZA at 
concentrations in t he ra nge of 10-• to 10-" M . Highe r co ncen-
t rations (lo-~ M) appeared to be cytotox ic a nd inhibited t he 
viability and growth of mela noma cells, but t his cytotox icity 
was nonspecific owin g to t he unfavo rable growth condi t ions 
result ing from perturbations of hydrogen ion co ncent ration. 
Nazzaro-Porro a nd Breathnach a nd their co lleagues have 
conducted clinical t ri a ls using AZA prepa rations [2-6,22], and 
some of t heir clinical photographs, histologic cri te ria, a nd mi -
tochondrial enzyme inhibi t ion studies indicate that AZA is 
cytotoxic to abnormal-appearing, pigment-producing cells . Be-
sides these studi es, there is one add it iona l repo rt on len t igo 
maligna confirming the effects of AZA on hyperactive and 
a bnormal-appearing mela nocytes [7]. Wills haw and Hubin-
stein , in 4 cases of ocular mela noma, have not found AZA to 
be effective in t he t reatment of huma n melanoma. Furthermore, 
a lthough t he AZA (12 g/day) in t he ir study was ge nera lly well 
tolerated, one of t heir patients deve loped severe hypokalemi a 
during the treatment [23]. 
Investigations on the acute tox icity o f AZA after ora l a nd i.p . 
administration , as reported by Mingrone et a! [1 9], indicate 
AZA is nontoxic a nd has no te ratoge nic e ffects . Our observa-
tions on mice, a lbeit limited in nature, a lso support t hese 
investigato rs' findin gs t hat AZA in t he physio logic dose range 
of 10-1; to 10--• M has no appa ren t toxic e ffect on the adult 
a nimal, but it is tox ic at high co nce nt rat ions, especia lly when 
AZA is administe red in unbuffered acid form . 
The obse rvations reported in t his communication raise a few 
majo r issues co ncernin g t he e ffects of C8-C 1 ~ dicarboxylic ac ids. 
F irst is it possible AZA, the C9 dicarboxylic acid, has no 
cytotoxicity to no rmal mela nocytes or atyp ica l malignant me-
la n ocytes, and othe r dica rboxy lic ac ids not investigated by us 
exhibit the selective inhibi to ry e ffect on ab normal melano-
cytes? Ce rtai nly, addi t iona l preclinical investigations a re wa r-
ran ted to confirm t he interesting findings reported by Nazzaro-
Porr o and other co investigators. The effect o f buffered a nd 
unbuffered AZA must be critically evaluated wi t h respect to 
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pH, co ncent rat ion , and systemic toxicity. The second issue is 
whether t hese saturated dica rboxylic acids ( C8-C 1 ~) in the ir in 
vivo oxidative metabolism generate metabolites which selec-
t ively damage mitochondrial membra nes and associated vital 
enzymes [24,25 ] or whether AZA significant ly reduces proli f-
eration of abnorm al cells only due to inhibi t ion of DNA syn -
thesis. Additional clinical and la boratory studies will have to 
be undertaken to determine the species differences and t he 
spec ific cytotox ic effect of t hese saturated medium cha in -length 
dicarboxylic acids on human malignant melanocytes a nd mel -
anoma ce lls from other species. Alternatively, it is possible AZA 
may have a specific effect in humans not see n in t he a nimal 
models and cell lines employed in t his study. 
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